Re: Aducanumab-Related ARIA: Paean or Lament?

Area of Science:

• Neurology
• Nuclear Medicine
• Biomarkers

Background:

• Alzheimer disease (AD) diagnosis relies on clinical assessment and biomarkers.
• Amyloid Positron Emission Tomography (PET) is a key imaging modality for detecting amyloid plaques, a hallmark of AD.

Purpose of the Study:

• To address concerns regarding the reliability of amyloid PET in excluding Alzheimer disease.
• To present additional studies on amyloid PET performance.
• To discuss diagnostic challenges and limitations of amyloid PET in AD.

Main Methods:

• Review of existing literature and studies on amyloid PET.
• Analysis of diagnostic accuracy and limitations of amyloid PET.
• Discussion of clinical implications for Alzheimer disease management.

Main Results:

• Amyloid PET may not be fully reliable for excluding Alzheimer disease.
• Diagnostic challenges persist in interpreting amyloid PET results.
• Limitations exist in using amyloid PET for evaluating therapy response in AD.

Conclusions:

• The reliability of amyloid PET to definitively exclude Alzheimer disease is questioned.
• Further research and careful interpretation are needed for amyloid PET in AD diagnosis.
• Limitations of amyloid PET impact its utility in assessing treatment efficacy.